Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleToxicology

Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response

Sebastien A. Burel, Todd Machemer, Frank L. Ragone, Hiroki Kato, Patrick Cauntay, Sarah Greenlee, Aneeza Salim, William A. Gaarde, Gene Hung, Raechel Peralta, Susan M. Freier and Scott P. Henry
Journal of Pharmacology and Experimental Therapeutics July 2012, 342 (1) 150-162; DOI: https://doi.org/10.1124/jpet.112.193789
Sebastien A. Burel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Machemer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank L. Ragone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Kato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Cauntay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Greenlee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aneeza Salim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Gaarde
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gene Hung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raechel Peralta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan M. Freier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott P. Henry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Antisense oligonucleotides (ASO) containing 2′-O-methoxyethyl ribose (2′-MOE) modifications have been shown to possess both excellent pharmacokinetic properties and robust pharmacological activity in several animal models of human disease. 2′-MOE ASOs are generally well tolerated, displaying minimal to mild proinflammatory effect at doses far exceeding therapeutic doses. Although the vast majority of 2′-MOE ASOs are safe and well tolerated, a small subset of ASOs inducing acute inflammation in mice has been identified. The mechanism for these findings is not clear at this point, but the effects are clearly sequence-specific. One of those ASOs, ISIS 147420, causes a severe inflammatory response atypical of this class of oligonucleotides characterized by induction in interferon-β (IFN-β) at 48 h followed by acute transaminitis and extensive hepatocyte apoptosis and necrosis at 72 h. A large number of interferon-stimulated genes were significantly up-regulated in liver as early as 24 h. We speculated that a specific sequence motif might cause ISIS 147420 to be mistaken for viral RNA or DNA, thus triggering an acute innate immune response. ISIS 147420 toxicity was independent of Toll-like receptors, because there was no decrease in IFN-β in Toll/interleukin-1 receptor-domain-containing adapter-inducing IFN-β or Myd88-deficient mice. The involvement of cytosolic retinoic acid-inducible gene (RIG)-I-like pattern recognition receptors was also investigated. Pretreatment of mice with melanoma differentiation-associated gene 5 (MDA5) and IFN-β promoter stimulator-1 ASOs, but not RIG-I or laboratory of genetics and physiology 2 (LGP2) ASOs, prevented the increase in IFN-β and alanine aminotransferase induced by ISIS 147420. These results revealed a novel mechanism of oligonucleotide-mediated toxicity requiring both MDA5 and IPS-1 and resulting in the activation of the innate immune response.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    http://dx.doi.org/10.1124/jpet.112.193789.

  • ↵Embedded Image The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

  • ABBREVIATIONS:

    ASO
    antisense oligonucleotide
    PS
    phosphorothioate
    MOE
    O-methoxyethyl ribose
    ALT
    alanine aminotransferase
    AST
    aspartate aminotransferase
    PRR
    pattern recognition receptor
    TLR
    Toll-like receptor
    FDR
    false discovery rate
    MDA5
    melanoma differentiation-associated gene 5
    RIG
    retinoic acid-inducible gene
    RLR
    RIG-I-like receptor
    IFN
    interferon
    IPS-1
    IFN-β promoter stimulator-1
    TRIF
    Toll/interleukin-1 receptor-domain-containing adapter-inducing IFN-β
    MYD88
    myeloid differentiation primary response gene 88
    KO
    knockout
    IPA
    Ingenuity Pathway Analysis
    TBST
    Tris-buffered saline/Tween 20
    ANOVA
    analysis of variance
    SDM
    standard deviation of mean
    STAT1
    signal transducer and activator of transcription 1
    HMGB
    high-mobility group box
    LGP2
    laboratory of genetics and physiology 2.

  • Received March 5, 2012.
  • Accepted April 12, 2012.
  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 342 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 342, Issue 1
1 Jul 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleToxicology

Atypical MDA5 Activation by Short Oligonucleotide

Sebastien A. Burel, Todd Machemer, Frank L. Ragone, Hiroki Kato, Patrick Cauntay, Sarah Greenlee, Aneeza Salim, William A. Gaarde, Gene Hung, Raechel Peralta, Susan M. Freier and Scott P. Henry
Journal of Pharmacology and Experimental Therapeutics July 1, 2012, 342 (1) 150-162; DOI: https://doi.org/10.1124/jpet.112.193789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleToxicology

Atypical MDA5 Activation by Short Oligonucleotide

Sebastien A. Burel, Todd Machemer, Frank L. Ragone, Hiroki Kato, Patrick Cauntay, Sarah Greenlee, Aneeza Salim, William A. Gaarde, Gene Hung, Raechel Peralta, Susan M. Freier and Scott P. Henry
Journal of Pharmacology and Experimental Therapeutics July 1, 2012, 342 (1) 150-162; DOI: https://doi.org/10.1124/jpet.112.193789
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of FXR in Nitrogen Mustard Lung Injury
  • Nafamostat is a Potent Human Diamine Oxidase Inhibitor
  • Chemoproteomics Investigation of Testicular Toxicity with BTK Inhibitor
Show more Toxicology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics